New Age Alpha Advisors LLC Buys Shares of 8,398 Penumbra, Inc. (NYSE:PEN)

New Age Alpha Advisors LLC purchased a new position in shares of Penumbra, Inc. (NYSE:PEN) in the fourth quarter, Holdings Channel.com reports. The firm purchased 8,398 shares of the company’s stock, valued at approximately $1,994,000.

Other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new position in Penumbra during the fourth quarter worth $573,000. State Street Corp increased its holdings in shares of Penumbra by 0.3% during the 3rd quarter. State Street Corp now owns 1,236,671 shares of the company’s stock valued at $240,298,000 after acquiring an additional 3,863 shares during the last quarter. E. Ohman J or Asset Management AB increased its holdings in shares of Penumbra by 10.4% during the 4th quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company’s stock valued at $5,061,000 after acquiring an additional 2,000 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Penumbra by 1.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company’s stock valued at $64,493,000 after acquiring an additional 3,807 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Penumbra by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 655,572 shares of the company’s stock worth $127,417,000 after purchasing an additional 11,257 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PEN. Needham & Company LLC reissued a “hold” rating on shares of Penumbra in a research report on Wednesday, February 19th. Robert W. Baird lifted their target price on shares of Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a report on Wednesday, February 19th. Wells Fargo & Company boosted their target price on shares of Penumbra from $275.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Citigroup raised their price target on Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Finally, Oppenheimer began coverage on Penumbra in a research report on Tuesday, December 17th. They set an “outperform” rating and a $275.00 price objective for the company. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $294.47.

Penumbra Trading Down 0.9 %

Shares of Penumbra stock opened at $267.16 on Monday. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $310.00. The firm has a market capitalization of $10.29 billion, a PE ratio of 785.75, a price-to-earnings-growth ratio of 2.83 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. The company’s fifty day moving average price is $274.55 and its two-hundred day moving average price is $243.18.

Penumbra (NYSE:PEN) last posted its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09. The business had revenue of $315.52 million for the quarter, compared to analysts’ expectations of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. On average, analysts expect that Penumbra, Inc. will post 3.67 EPS for the current year.

Insider Transactions at Penumbra

In other Penumbra news, Director Harpreet Grewal sold 167 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $241.28, for a total transaction of $40,293.76. Following the completion of the transaction, the director now directly owns 8,530 shares in the company, valued at $2,058,118.40. This represents a 1.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Maggie Yuen sold 2,000 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $286.00, for a total transaction of $572,000.00. Following the completion of the sale, the chief financial officer now owns 15,243 shares in the company, valued at $4,359,498. This represents a 11.60 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 93,518 shares of company stock valued at $26,400,219. Corporate insiders own 5.00% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.